{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:20:40Z","timestamp":1772166040277,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010451","name":"Health and Family Planning Commission of Hunan Province","doi-asserted-by":"publisher","award":["20200022"],"award-info":[{"award-number":["20200022"]}],"id":[{"id":"10.13039\/501100010451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2021zzts1010"],"award-info":[{"award-number":["2021zzts1010"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Immune checkpoint inhibitors (ICIs) and targeted treatments have improved the health outcomes of patients with advanced melanoma. However, due to the high cost of novel therapies, it is crucial to evaluate their value by considering both effectiveness and cost. To compare the cost-effectiveness of these novel agents (atezolizumab-vemurafenib-cobimetinib, vemurafenib-plus-cobimetinib, dabrafenib-plus-trametinib, and encorafenib-plus-binimetinib) for first-line treatment of metastatic melanoma with the BRAF\n                      <jats:sup>V600<\/jats:sup>\n                      mutation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A patient-level model was developed to project the health outcomes of 4 strategies for patients with advanced melanoma. We estimated transition probabilities from the IMspire150 (ClinicalTrials.gov, NCT02908672), COMBI-AD (NCT01682083), and COLUMBUS (NCT01909453) trials using a parametric survival model. All health outcomes, including direct cost, quality-adjusted life-years (QALYs) and the incremental cost-effectiveness ratio (ICER), were estimated from the US payer perspective. Lifetime cost, QALYs, life-years (LYs), and ICERs were calculated. Univariable and probabilistic sensitivity analyses were performed to test model robustness, along with multiple scenario analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 4 competing strategies, atezolizumab-vemurafenib-cobimetinib produced the best health outcomes, and the vemurafenib-cobimetinib strategy was the least expensive option. Atezolizumab-vemurafenib-cobimetinib, dabrafenib-plus-trametinib, and vemurafenib-cobimetinib formed the cost-effective frontier, indicating that the ordered ICERs were $325,113\/QALYs for dabrafenib-plus-trametinib vs. vemurafenib-cobimetinib strategies and $2,247,500\/QALYs for atezolizumab-vemurafenib-cobimetinib vs. dabrafenib-plus-trametinib strategies. Encorafenib-plus-binimetinib was dominated by the other 3 competing strategies. The drug price and first-line utility significantly influenced the model utcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For BRAF-mutant advanced melanoma, the vemurafenib-cobimetinib strategy could be considered the most cost-effective treatment at the willingness-to-pay threshold of $150,000.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-023-09058-7","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T06:02:59Z","timestamp":1674021779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Si Ni","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu Bao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian He","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"9058_CR1","unstructured":"Stigler KA, Mcdougle CJ, Scahill L, Aman MG, Eugene AL, Johnson C. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Effectiveness and tolerability of aripiprazole in risperidone nonresponders. Neuropsychopharmacology. 2011;36:S228."},{"issue":"6","key":"9058_CR2","first-page":"1005","volume":"28","author":"M Rastrelli","year":"2014","unstructured":"Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28(6):1005\u201311.","journal-title":"In Vivo"},{"issue":"1","key":"9058_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1001\/jamadermatol.2018.3958","volume":"155","author":"AR Almutairi","year":"2019","unstructured":"Almutairi AR, Alkhatib NS, Oh M, et al. Economic evaluation of Talimogene Laherparepvec plus Ipilimumab combination therapy vs Ipilimumab monotherapy in patients with advanced Unresectable melanoma. JAMA Dermatol. 2019;155(1):22\u20138.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"9058_CR4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1200\/JCO.2016.69.6336","volume":"35","author":"CG Kohn","year":"2017","unstructured":"Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR. Cost-effectiveness of immune checkpoint inhibition in BRAF wild-type advanced melanoma. J Clin Oncol. 2017;35(11):1194\u2013202.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9058_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/1362361304045212","volume":"8","author":"V Bernard-Opitz","year":"2004","unstructured":"Bernard-Opitz V, Ing S, Kong TY. Comparison of behavioural and natural play interventions for young children with autism. Autism. 2004;8(3):319\u201333.","journal-title":"Autism"},{"issue":"14","key":"9058_CR6","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2217\/imt-2018-0085","volume":"10","author":"A Tarhini","year":"2018","unstructured":"Tarhini A, Benedict A, McDermott D, et al. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. Immunotherapy. 2018;10(14):1241\u201352.","journal-title":"Immunotherapy"},{"issue":"1\u20132","key":"9058_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/0954026021000046119","volume":"15","author":"E Fombonne","year":"2003","unstructured":"Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R. Prevalence of pervasive developmental disorders in the British nationwide survey of child mental health. Int Rev Psychiatry. 2003;15(1\u20132):158\u201365.","journal-title":"Int Rev Psychiatry"},{"issue":"12","key":"9058_CR8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40265-018-0945-z","volume":"78","author":"N Malissen","year":"2018","unstructured":"Malissen N, Grob JJ. Metastatic melanoma: recent therapeutic Progress and future perspectives. Drugs. 2018;78(12):1197\u2013209.","journal-title":"Drugs"},{"issue":"10240","key":"9058_CR9","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2020;395(10240):1835\u201344.","journal-title":"Lancet (London, England)"},{"issue":"10","key":"9058_CR10","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315\u201327.","journal-title":"Lancet Oncol"},{"issue":"19","key":"9058_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813\u201323.","journal-title":"N Engl J Med"},{"issue":"24","key":"9058_CR12","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.1158\/1078-0432.CCR-14-1457","volume":"20","author":"SJ Antonia","year":"2014","unstructured":"Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res. 2014;20(24):6258\u201368.","journal-title":"Clin Cancer Res"},{"issue":"7695","key":"9058_CR13","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1038\/d41586-018-02483-3","volume":"555","author":"E Dolgin","year":"2018","unstructured":"Dolgin E. Bringing down the cost of cancer treatment. Nature. 2018;555(7695):S26\u20139.","journal-title":"Nature"},{"issue":"15","key":"9058_CR14","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","volume":"276","author":"MC Weinstein","year":"1996","unstructured":"Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253\u20138.","journal-title":"JAMA"},{"issue":"9","key":"9058_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"issue":"7","key":"9058_CR16","first-page":"1","volume":"68","author":"E Arias","year":"2019","unstructured":"Arias E. United States life tables, 2017. Natl Vital Stat Rep. 2019;68(7):1\u201366.","journal-title":"Natl Vital Stat Rep"},{"issue":"4","key":"9058_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.","journal-title":"Lancet Oncol"},{"issue":"2","key":"9058_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/ije\/dym062","volume":"36","author":"D Caldwell","year":"2007","unstructured":"Caldwell D. Decision modelling for health economic evaluation. A Briggs, M Sculpher, K Claxton. Int J Epidemiol. 2007;36(2):476\u20137.","journal-title":"Int J Epidemiol"},{"key":"9058_CR19","doi-asserted-by":"publisher","first-page":"718014","DOI":"10.3389\/fphar.2021.718014","volume":"12","author":"S Li","year":"2021","unstructured":"Li S, Li J, Peng L, Li Y, Wan X. Cost-effectiveness of frontline treatment for advanced renal cell carcinoma in the era of immunotherapies. Front Pharmacol. 2021;12:718014.","journal-title":"Front Pharmacol"},{"key":"9058_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"9058_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"3","key":"9058_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/famp.12016","volume":"52","author":"G Roux","year":"2013","unstructured":"Roux G, Sofronoff K, Sanders M. A randomized controlled trial of group stepping stones triple P: a mixed-disability trial. Fam Process. 2013;52(3):411\u201324.","journal-title":"Fam Process"},{"issue":"5","key":"9058_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0145445511405513","volume":"35","author":"H Kovshoff","year":"2011","unstructured":"Kovshoff H, Hastings RP, Remington B. Two-year outcomes for children with autism after the cessation of early intensive behavioral intervention. Behav Modif. 2011;35(5):427\u201350.","journal-title":"Behav Modif"},{"issue":"6","key":"9058_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1469-7610.2005.01567.x","volume":"47","author":"C Kasari","year":"2006","unstructured":"Kasari C, Freeman S, Paparella T. Joint attention and symbolic play in young children with autism: a randomized controlled intervention study. J Child Psychol Psychiatry Allied Disciplines. 2006;47(6):611\u201320.","journal-title":"J Child Psychol Psychiatry Allied Disciplines"},{"issue":"6","key":"9058_CR25","doi-asserted-by":"publisher","first-page":"653","DOI":"10.18553\/jmcp.2017.23.6.653","volume":"23","author":"A Oh","year":"2017","unstructured":"Oh A, Tran DM, McDowell LC, et al. Cost-effectiveness of Nivolumab-Ipilimumab combination therapy compared with monotherapy for first-line treatment of metastatic melanoma in the United States. J Managed Care Specialty Pharm. 2017;23(6):653\u201364.","journal-title":"J Managed Care Specialty Pharm"},{"issue":"1","key":"9058_CR26","doi-asserted-by":"publisher","first-page":"e2033441","DOI":"10.1001\/jamanetworkopen.2020.33441","volume":"4","author":"KK Patel","year":"2021","unstructured":"Patel KK, Stein S, Lacy J, O'Hara M, Huntington SF. Evaluation of the cost-effectiveness of doublet therapy in metastatic BRAF variant colorectal Cancer. JAMA Netw Open. 2021;4(1):e2033441.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"9058_CR27","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1007\/s12325-021-01627-8","volume":"38","author":"S Li","year":"2021","unstructured":"Li S, Hu H, Ding D, Zhu Y, Huang J. Cost-effectiveness analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-mutated metastatic colorectal cancer in the USA. Adv Ther. 2021;38(3):1650\u20139.","journal-title":"Adv Ther"},{"key":"9058_CR28","doi-asserted-by":"crossref","unstructured":"Wu B, Shi L. Frontline BRAF Testing\u2013Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data. JAMA dermatology. 2020;156(11):1177-84.","DOI":"10.1001\/jamadermatol.2020.2398"},{"issue":"11","key":"9058_CR29","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1007\/s10803-020-04729-4","volume":"51","author":"RYF Ho","year":"2021","unstructured":"Ho RYF, Zhang D, Chan SKC, et al. Brief report: mindfulness training for Chinese adolescents with autism Spectrum disorder and their parents in Hong Kong. J Autism Dev Disord. 2021;51(11):4147\u201359.","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"9058_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.rasd.2010.04.001","volume":"5","author":"MC Cappadocia","year":"2011","unstructured":"Cappadocia MC, Weiss JA. Review of social skills training groups for youth with Asperger syndrome and high functioning autism. Res Autism Spectr Disord. 2011;5(1):70\u20138.","journal-title":"Res Autism Spectr Disord"},{"key":"9058_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12955-014-0140-1","volume":"12","author":"AJ Hatswell","year":"2014","unstructured":"Hatswell AJ, Pennington B, Pericleous L, Rowen D, Lebmeier M, Lee D. Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health Qual Life Outcomes. 2014;12:140.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"9058_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6605187","volume":"101","author":"KM Beusterien","year":"2009","unstructured":"Beusterien KM, Szabo SM, Kotapati S, et al. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer. 2009;101(3):387\u20139.","journal-title":"Br J Cancer"},{"issue":"18","key":"9058_CR33","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1056\/NEJMsa1203980","volume":"367","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Baik SH, Fendrick AM, Baicker K. Comparing local and regional variation in health care spending. N Engl J Med. 2012;367(18):1724\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"9058_CR34","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jval.2011.04.004","volume":"14","author":"B Goulart","year":"2011","unstructured":"Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health. 2011;14(6):836\u201345.","journal-title":"Value Health"},{"issue":"8","key":"9058_CR35","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1185\/03007995.2015.1062356","volume":"31","author":"EL Toy","year":"2015","unstructured":"Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr Med Res Opin. 2015;31(8):1561\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"9058_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.18553\/jmcp.2015.21.2.158","volume":"21","author":"B Arondekar","year":"2015","unstructured":"Arondekar B, Curkendall S, Monberg M, et al. Economic burden associated with adverse events in patients with metastatic melanoma. J Managed Care Specialty Pharm. 2015;21(2):158\u201364.","journal-title":"J Managed Care Specialty Pharm"},{"issue":"6","key":"9058_CR37","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/CMR.0000000000000097","volume":"24","author":"F Vekeman","year":"2014","unstructured":"Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS. Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population. Melanoma Res. 2014;24(6):602\u201310.","journal-title":"Melanoma Res"},{"issue":"5","key":"9058_CR38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.amepre.2012.07.031","volume":"43","author":"GP Guy Jr","year":"2012","unstructured":"Guy GP Jr, Ekwueme DU, Tangka FK, Richardson LC. Melanoma treatment costs: a systematic review of the literature, 1990-2011. Am J Prev Med. 2012;43(5):537\u201345.","journal-title":"Am J Prev Med"},{"issue":"1","key":"9058_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/eurpub\/ckab042","volume":"32","author":"L Gassner","year":"2022","unstructured":"Gassner L, Geretsegger M, Mayer-Ferbas J. Effectiveness of music therapy for autism spectrum disorder, dementia, depression, insomnia and schizophrenia: update of systematic reviews. Eur J Pub Health. 2022;32(1):27\u201334.","journal-title":"Eur J Pub Health"},{"key":"9058_CR40","doi-asserted-by":"crossref","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20131. Medical Decision Making. 2012;32(5):667-77.","DOI":"10.1177\/0272989X12454577"},{"key":"9058_CR41","volume-title":"Microsimulation approaches","author":"MJSC Spielauer","year":"2009","unstructured":"Spielauer MJSC. Microsimulation approaches; 2009."},{"key":"9058_CR42","doi-asserted-by":"crossref","unstructured":"Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma. Journal of Clinical Oncology. 2021;39(10):1119-28.","DOI":"10.1200\/JCO.20.01849"},{"issue":"17","key":"9058_CR43","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood.2020004922","volume":"136","author":"KK Patel","year":"2020","unstructured":"Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood. 2020;136(17):1946\u201355.","journal-title":"Blood"},{"key":"9058_CR44","doi-asserted-by":"crossref","unstructured":"Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma. Journal of Clinical Oncology. 2018;36(33):3307.","DOI":"10.1200\/JCO.18.00122"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09058-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-09058-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09058-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T06:05:35Z","timestamp":1674021935000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-09058-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["9058"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-09058-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1773968\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"20 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a model-based economic evaluation for which the patient data were all obtained from previous published studies. It does not contain any studies with animal or human participants. Therefore, ethics approval and consent to participate are no needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not application.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no conflict of interest between all authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}